Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.

医学 卡培他滨 胸腺癌 吉西他滨 中性粒细胞减少症 胸腺瘤 内科学 胃肠病学 临床终点 化疗 临床研究阶段 外科 进行性疾病 毒性 肿瘤科 癌症 临床试验 结直肠癌
作者
Carlo Buonerba,Margaret Ottaviano,Piera Federico,F Calabrese,Claudia von Arx,Simona Iaccarino,Lucia Nappi,Irene Tucci,Giuseppe Di Lorenzo,Elide Matano,Vincenzo Damiano,Giovannella Palmieri
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:32 (15_suppl): 7528-7528 被引量:5
标识
DOI:10.1200/jco.2014.32.15_suppl.7528
摘要

7528 Background: Thymic epithelial tumors (TETs) are rare malignancies, with an estimated incidence of about 3 cases per 100,000 inhabitants. No standard treatment is available for recurrent disease. In 2005, a multi-institutional phase II trial was started on the combination of gemcitabine and capecitabine in pretreated patients with TETs. Final results of this phase II study are presented. Methods: Eligibility criteria for the study were mainly the following: histologic diagnosis of TET by central review; at least one prior systemic chemotherapy treatment; progressive disease. Treatment consisted of oral capecitabine (650 mg/mq twice daily on days 1–14) and i.v. gemcitabine (1000 mg/mq on days 1 and 8) every 3 weeks. The radiographic response rate was chosen as primary end point and employed to calculate the study sample. Secondary end points were progression-free survival, toxicity, and overall survival. Results: Thirty patients (18 men, 12 women; median age 57 years, range 48–61 years)were enrolled in this phase II trial from November, 2005 to June 2013. The majority of patients (73%) had thymoma, while the remaining had thymic carcinoma.Of note, 63% of patients showed disease progression within 2 months from the last dose of the last systemic therapy received. The most important grade 3 toxicity was neutropenia in eight patients. Twelve patients had a response (three complete responses and eight partial responses). Among thymic carcinoma patients, we observed three partial responses. Median PFS was 11 months (95% CI 3–17 months). The PFS for patients with thymoma and thymic carcinoma was 11 months (95% CI 6–17 months) and 6 months (95% CI 3–11 months), respectively. Thirteen patients are dead at the time of the analysis (median OS, 16 months). Conclusions: Capecitabine and gemcitabine is a highly active combination therapy in thymic epithelial tumors and should be routinely included in the managment of recurrent/metastatic disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Leo000007发布了新的文献求助10
2秒前
希望天下0贩的0应助lcy采纳,获得10
6秒前
药化小硕完成签到,获得积分10
7秒前
FashionBoy应助吴未采纳,获得10
7秒前
汉堡包应助卡皮巴拉采纳,获得10
10秒前
TTTaT完成签到,获得积分10
11秒前
11秒前
壮观以松发布了新的文献求助10
12秒前
搜集达人应助王大锤采纳,获得20
13秒前
lpp_完成签到 ,获得积分10
17秒前
二一而已发布了新的文献求助10
18秒前
尔信完成签到 ,获得积分10
18秒前
18秒前
18秒前
修脚大师完成签到,获得积分10
21秒前
YL发布了新的文献求助10
23秒前
爱吃巧克力给爱吃巧克力的求助进行了留言
24秒前
陈莲花完成签到,获得积分10
24秒前
27秒前
28秒前
29秒前
29秒前
30秒前
30秒前
32秒前
Harvey3568发布了新的文献求助10
33秒前
ChenYX发布了新的文献求助10
34秒前
34秒前
单于万言发布了新的文献求助10
35秒前
35秒前
吴未发布了新的文献求助10
35秒前
郭郭郭发布了新的文献求助10
35秒前
贺万万发布了新的文献求助10
36秒前
三叁发布了新的文献求助10
37秒前
dazi完成签到,获得积分10
38秒前
依久九九发布了新的文献求助10
38秒前
38秒前
34Kenny发布了新的文献求助10
38秒前
keyandog发布了新的文献求助10
40秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
The diagnosis of sex before birth using cells from the amniotic fluid (a preliminary report) 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3229344
求助须知:如何正确求助?哪些是违规求助? 2877046
关于积分的说明 8197662
捐赠科研通 2544371
什么是DOI,文献DOI怎么找? 1374357
科研通“疑难数据库(出版商)”最低求助积分说明 646946
邀请新用户注册赠送积分活动 621742